Apple Glass Concept

Apple Glass Concept Shows Us All the AR Goodness We Need

These days smart glasses are back in full force, courtesy of some leaks supposedly coming from Apple. Turns out the Cupertino giant is prepping two wearables, one VR headset for gamers coming next year and one AR coming in 2022, looking more like regular glasses. The latter has been rendered in concept form by user the hacker 34.

It’s also a good way to see how these glasses would work. The device is called Apple Glass here and looks very much like a pair of regular glasses. It’s got an advanced LiDAR scanner on the left side of the frame, plus a light sensor, microphone and proximity sensor on the other side (top and front). At the middle, right above the nose sits the dual core G1 CPU. the lenses are dual transparent Retina screens. The designer envisions a so called rOS, inspired by iOS.

There are Home Cards available, basically a sort of widgets that show useful info. You can navigate with air swipes and the interface changes with the ambient light around. There’s AR navigation for map orientation shown in the video and real object detection, like iPhones for example. Calls are taken with the aids of the AirPods Pro. We don’t get specs, materials used for the lenses and frames, battery power, resolution and all that. It’s more of a proof of concept… which was done in PowerPoint by the way.

I actually dig the interface, but I’m not very sure about swiping in mid air to navigate. Swiping on the frame is also an option, but it sounds equally annoying. Voice command is probably the way to go, or maybe even eye movements/gestures. Also, you should remember about the theory that says the Apple Glasses will be bundled with a smart ring that you’ll put on your finger in order to control the UI. I would love to see THAT rendered.

via wccftech

India Covid-19 vaccine by August 15

India races to release first indigenous Covid-19 vaccine by August 15

Covaxin, India’s indigenous vaccine candidate for the coronavirus, is slated to be launched on August 15, according to the ICMR. Human clinical trials for the vaccine—which is being jointly developed by Bharat Biotech and ICMR-NIV—are set to begin this month, after the drug regulator gave approval for phase one and two human trials.

The ICMR has asked these institutes to fast-track clinical trials of the vaccine as it is being considered as one of the “top priority projects”.

The ICMR said that it is envisaged to launch the Covid-19 vaccine for public health use latest by August 15.(Representative Photo/Reuters)

The Indian Council of Medical Research (ICMR) has partnered with Bharat Biotech International Limited (BBIL) for clinical trials of indigenous vaccine for the coronavirus disease.BBIL is using the virus strain isolated at ICMR’s National Institute of Virology (NIV) in Pune to develop the vaccine.The clinical trials will be held in 12 institutes across the country. 

The ICMR has asked these institutes to fast-track clinical trials of the vaccine as it is being considered as one of the “top priority projects” which are being “monitored at the topmost level of the government”.In a letter to these institutes, the ICMR said that it is envisaged to launch the vaccine for public health use latest by August 15, after completion of all clinical trials.“BBIL is working expeditiously to meet the target, however, the final outcome will depend on the cooperation of all clinical trial sites involved in this project,” it further said in the letter.

It has also asked the institutes to ensure that the subject enrolment is initiated during the first week of July.Apart from IMS and SUM Hospital here, the other institutes selected for the clinical trial are located in Visakhapatnam, Rohtak, New Delhi, Patna, Belgaum (Karnataka), Nagpur, Gorakhpur, Kattankulathur (Tamil Nadu), Hyderabad, Arya Nagar, Kanpur (Uttar Pradesh) and Goa.Meanwhile, the Drug Controller General of India (DCGI) on Thursday granted permission to pharma giant Zydus Cadila to conduct phase I and phase II human clinical trials for Covid-19 vaccine.The potential vaccine showed a “strong immune response” in animal studies, and the antibodies produced were able to completely neutralise the wild type virus, Zydus, part of Cadila Healthcare Ltd, said in a statement to Indian stock exchanges.Zydus will begin human trials this month in over 1,000 subjects in multiple sites in India, it said.